
Aurobindo Pharma Share Price in 2025: Chart, Monthly Trends, & Analysis


How did Aurobindo Pharma shares perform in 2025?
Let's find out!
Aurobindo Pharma share price in 2025 was ₹1,124.8 Its price on 1st January 2025 was ₹1,334.85, and by 31st December 2025 it moved to ₹1,124.8, giving a negative return of -15.74% for the year.
Aurobindo Pharma Share Open, High, Low, and Close prices for the Year 2025 are as follows:
Open | High | Low | Close |
---|---|---|---|
₹1,334.85 | ₹1,356.2 | ₹1,010 | ₹1,124.8 |
1st Jan 2025 | Occured in Jan 2025 | Occured in Apr 2025 | 31st Dec 2025 |
This page will help you understand how Aurobindo Pharma performed in 2025. Let's get started.
For complete insights into Aurobindo Pharma’s incredible stock price performance and growth, see: Aurobindo Pharma Historical Share Price Data from its IPO to 2025
Table: Aurobindo Pharma Share Monthly Close, Low, High Prices for 2025
Month | Aurobindo Pharma | Change% | ↑High - ↓Low |
---|---|---|---|
Jan | ₹1,171.9 | - |
↑ ₹1,356.2 ↓ ₹1,133.05 |
Feb | ₹1,058.3 | -9.7% |
↑ ₹1,219.9 ↓ ₹1,052.7 |
Mar | ₹1,160.5 | 9.6% |
↑ ₹1,230.7 ↓ ₹1,031.05 |
Apr | ₹1,229.09 | 5.9% |
↑ ₹1,278.59 ↓ ₹1,010 |
May | ₹1,147.8 | -6.7% |
↑ ₹1,251.4 ↓ ₹1,119.9 |
Jun | ₹1,134.8 | -1.2% |
↑ ₹1,194.3 ↓ ₹1,078.5 |
Jul | ₹1,124.8 | -0.9% |
↑ ₹1,197 ↓ ₹1,112 |
Chart: CandleStick and Line Chart Showing Monthly Prices
[Click on line name to show/hide a line]
What if You invested ₹10,000 in Aurobindo Pharma in 2025?
In 2025, the opening price of Aurobindo Pharma share was ₹1334.85. Today, the price stands at ₹1,124.8, reflecting a growth of -15.74%. If we applying the same growth to your investment of ₹10,000 then, your investment of ₹10,000 in 2025 would have become ₹8,426.41 by 2025. This represents a CAGR of -15.74%.
You might also like to check: Aurobindo Pharma Stock Price in 2024
References:
Stock prices on stockpricearchive.com are gathered from reliable sources only. We take prices from stock exchanges only, majorly from BSE and NSE.
Disclaimer: Information is provided ‘as is’ and solely for informational purposes, not for trading purposes or advice.